by Alison Bass | Nov 17, 2011 | biotech industry, clinical trials, conflicts of interest, patient care, pharmaceutical industry, Uncategorized, university industry collaboration
We’ve all signed those vague privacy statements when visiting our local hospital for medical care. But how many of us have actually read the fine print and understand that the most sensitive details of our medical lives may be shared with drug companies for...
by Alison Bass | Nov 2, 2011 | antipsychotic drugs, conflicts of interest, drug marketing, ghostwriting, patient care, pharmaceutical industry, scientific misconduct, Uncategorized
On November 28, the Texas Attorney General is expected to begin a landmark trial against Johnson & Johnson on charges that the pharmaceutical giant “subverted scientific integrity” by paying off academic psychiatrists and state officials to boost the...
by Alison Bass | Jun 14, 2011 | pharmaceutical industry, Uncategorized, university industry collaboration
I was planning to blog about Pfizer’s new $100 million partnership with several Boston-area medical centers and its potential downsides. But before I could get around to doing that, I was invited to talk about the deal on WGBH-TV’s Greater Boston show...
by Alison Bass | May 3, 2011 | Uncategorized
Stan Kutcher, the psychiatrist turned politician who threatened to sue The Coast newspaper in Halifax unless it issued a retraction on a story it did about Kutcher’s involvement with Paxil study 329 (see retracted story here) and my blog about it), lost...
by Alison Bass | May 1, 2011 | Uncategorized
In recent years, experts (like Bill Kovach and Tom Rosenstiel) have warned that press freedoms are under increasing threat from economic pressures. As advertising and readers flee to the Web, they say, news outlets are more likely to cave in to pressure from corporate...
by Alison Bass | Apr 25, 2011 | Uncategorized
In 2006, researchers first published results from a $35 million NIMH-funded study of antidepressants known as STAR*D, claiming it proved the effectiveness of second-generation antidepressants used alone and in combination with each other. The NIMH chimed in with press...
